# A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients

> **NCT02550535** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cell Medica Ltd** · enrollment: 3 (actual)

## Conditions studied

- Myelodysplastic Syndromes (MDS)
- Acute Myeloid Leukaemia (AML)

## Interventions

- **GENETIC:** Autologous WT1 TCR transduced T cells

## Key facts

- **NCT ID:** NCT02550535
- **Lead sponsor:** Cell Medica Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2018-05
- **Final completion:** 2018-05
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2018-10-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02550535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02550535, "A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02550535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*